Plasma Levels of miR-125b-5p and miR-206 in Acute Ischemic Stroke Patients After Recanalization Treatment: A Prospective Observational Study

He, Xianghuo; Shi, Yan-Hui; Zhao, Rong; Liu, Yi‐Sheng; Li, Gefei; Hu, Yue; Chen, Wei; Cui, Guo-Hong; Su, Jingjing; Liu, Jian-Ren

doi:10.1016/j.jstrokecerebrovasdis.2019.02.026

Cited by 22 publications

(23 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MiR-206, a muscle-enriched miRNA (myomiR), has an important role in myogenic differentiation [ 28 ]. MiR-206 was reported to be positively correlated with stroke severity [ 29 , 30 ] in humans and infarct volume in an animal model of embolic stroke [ 31 ], serving as a detrimental biomarker. Overexpression of miR-206 inhibits neuronal cell viability and proliferation, interfering with neurodevelopment [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Serum microRNA miR-491-5p/miR-206 Is Correlated with Poor Outcomes/Spontaneous Hemorrhagic Transformation after Ischemic Stroke: A Case Control Study

et al. 2022

View full text Add to dashboard Cite

Background: It is unclear whether miR-491-5p, miR-206, miR-21-5p or miR-3123 are associated with functional outcomes and hemorrhagic transformation (HT) after acute ischemic stroke (AIS). In this study, we aimed to investigate the correlation between these four microRNAs and functional outcomes, as well as spontaneous HT after AIS; Methods: We included 215 AIS patients and retrospectively assayed for miR-21-5p, miR-206, miR-3123 and miR-491-5p levels in serum. Poor functional outcome was defined as a modified Rankin Scale score ≥ 3. Spontaneous HT referred to hemorrhage detected in follow-up brain imaging but not on admission, without reperfusion therapies. Logistic regression, generalized additive model and 2-piecewise regression model were used to explore the independent, non-linear correlation between miRNA expression levels and outcomes; Results: We included 215 AIS patients. Higher miR-491-5p level independently reduced the risk of poor functional outcomes at 1 year (OR 0.90, 95% CI 0.82–0.98, corrected p value = 0.044). Higher miR-206 level significantly increased the risk of spontaneous HT (OR 1.64, 95% CI 1.17–2.30, corrected p value = 0.016). There was a nonlinear correlation found between miR-491-5p level and 1 year outcome with an inflection point of 2.180, while an approximately linear correlation was observed with an inflection point of 2.037 between miR-206 level and spontaneous HT; Conclusions: Higher serum miR-491-5p level independently reduced risk of 1-year poor functional outcome of AIS patients. Higher serum miR-206 level independently increased the risk of spontaneous HT in AIS patients. These two miRNAs may be as the potential biomarkers for improving prognosis after AIS.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum microRNA miR-491-5p/miR-206 Is Correlated with Poor Outcomes/Spontaneous Hemorrhagic Transformation after Ischemic Stroke: A Case Control Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…An in vivo experiment demonstrated that miR-125a-5p regulates blood brain barrier function [14]. MiR-125b-5p has previously been shown to be a predictive biomarker candidate for ischemic stroke outcomes [15,16]. MiR-433 is highly expressed in the brain tissue [11].…”

Section: Discussionmentioning

confidence: 99%

Serum miRNA125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to differentiate between posterior circulation stroke and peripheral vertigo

et al. 2020

View full text Add to dashboard Cite

Background Acute vertigo is a common presentation of inner ear disease. However, it can also be caused by more serious conditions, especially posterior circulation stroke. Differentiating between these two conditions by clinical presentations and imaging studies during the acute phase can be challenging. This study aimed to identify serum microRNA (miRNA) candidates that could differentiate between posterior circulation stroke and peripheral vertigo, among patients presenting with acute vertigo. Methods Serum levels of six miRNAs including miR-125a-5p, miR-125b-5p, miR-143-3p, miR-342-3p, miR-376a-3p, and miR-433-5p were evaluated. Using quantitative reverse-transcription polymerase chain reaction (RT-qPCR), the serum miRNAs were assessed in the acute phase and at a 90 day follow-up visit. Results A total of 58 patients with posterior circulation stroke (n = 23) and peripheral vertigo (n = 35) were included in the study. Serum miR-125a-5p (P = 0.001), miR-125b-5p (P < 0.001), miR-143-3p (P = 0.014) and miR-433-5p (P = 0.0056) were present at significantly higher levels in the acute phase, in the patients with posterior circulation infarction. Based on the area under the receiver operating characteristic curve (AUROC) only miR-125a-5p (0.75), miR-125b-5p(0.77), and miR-433-5p (0.71) had an acceptable discriminative ability to differentiate between the central and peripheral vertigo. A combination of miRNAs revealed no significant improvement of AUROC when compared to single miRNAs. Conclusion This study demonstrated the potential of serum miR-125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to assist in the diagnosis of posterior circulation infarction among patients presenting with acute vertigo.

show abstract

“…Bone marrow derived mesenchymal stem cells EVs have been reported to home in the infarct area after transplantation and have therapeutic effects such as endogenous neurogenesis, increase the number of axons, and improve vital functions of animals [ 63 , 64 ]. When incorporated with different miRNAs, MSC-derived EVs were able to promote a neuroprotective response [ [65] , [66] , [67] ]. In some studies, MSCs overexpressing specific miRNAs were chosen and were able to be passed on to the daughter EVs.…”

Section: Future Treatments: Limiting Reperfusion Damage and Recovering From Ischemic Strokementioning

confidence: 99%

Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine

Hurd

Goel

Sakai

et al. 2021

Regenerative Therapy

View full text Add to dashboard Cite

Ischemic stroke is a major cause of death and disability worldwide and is expected to increase in the future with the aging population. Currently, there are no clinically available treatments for damage sustained during an ischemic stroke, but much research is being conducted in this area. In this review, we will introduce current ischemic stroke treatments along with their limitations, as well as research on potential short and long-term future treatments. There are advantages and disadvantages in these potential treatments, but our understanding of these methods and their effectiveness in clinical trials are improving. We are confident that some future treatments introduced in this review will become commonly used in clinical settings in the future.

show abstract

Plasma Levels of miR-125b-5p and miR-206 in Acute Ischemic Stroke Patients After Recanalization Treatment: A Prospective Observational Study

Cited by 22 publications

References 37 publications

Serum microRNA miR-491-5p/miR-206 Is Correlated with Poor Outcomes/Spontaneous Hemorrhagic Transformation after Ischemic Stroke: A Case Control Study

Serum microRNA miR-491-5p/miR-206 Is Correlated with Poor Outcomes/Spontaneous Hemorrhagic Transformation after Ischemic Stroke: A Case Control Study

Serum miRNA125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to differentiate between posterior circulation stroke and peripheral vertigo

Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine

Contact Info

Product

Resources

About